-24.6%
TOST vs MRNA
-25.9%
+1.3%
-71.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.0% | -4.8% | +5.9% | +1.4% |
| 7D | -0.3% | -20.9% | +20.6% | +1.6% |
| 30D | +8.1% | -13.3% | +21.4% | +9.0% |
| 3M | -2.7% | +212.6% | -215.3% | -18.7% |
| 6M | +50.2% | +309.0% | -258.9% | +16.7% |
| YTD | -4.3% | +567.3% | -571.6% | -35.8% |
| 1Y | +0.8% | +689.7% | -688.9% | -35.5% |
| 3Y | +136.1% | +157.4% | -21.3% | +79.3% |
| All | -24.6% | -25.9% | +1.3% | -27.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling